M
Mirtha Guitelman
Researcher at University of Buenos Aires
Publications - 35
Citations - 1367
Mirtha Guitelman is an academic researcher from University of Buenos Aires. The author has contributed to research in topics: Acromegaly & Pegvisomant. The author has an hindex of 10, co-authored 32 publications receiving 1191 citations. Previous affiliations of Mirtha Guitelman include University of Helsinki.
Papers
More filters
Journal ArticleDOI
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line AIP Mutations and Pituitary Adenomas: An International Collaborative Study
Adrian Daly,Maria A. Tichomirowa,Patrick Petrossians,Elina Heliövaara,Marie Lise Jaffrain-Rea,Anne Barlier,Luciana Ansaneli Naves,Tapani Ebeling,Auli Karhu,Antti Raappana,Laure Cazabat,Ernesto De Menis,Carmen Fajardo Montañana,Gérald Raverot,Robert J. Weil,Timo Sane,Dominique Maiter,Sebastian J C M M Neggers,Maria Yaneva,AntoineAntoine Tabarin,Elisa Verrua,Eija Eloranta,Arnaud Murat,Outi Vierimaa,Pasi I. Salmela,Philippe Emy,Rodrigo A. Toledo,Maria Isabel Sabaté,Chiara Villa,Chiara Villa,Marc Popelier,Roberto Salvatori,Juliet Jennings,Ángel Ferrández Longás,José Ignacio Labarta Aizpún,Marianthi Georgitsi,Ralf Paschke,Cristina L. Ronchi,Matti Välimäki,Carola Saloranta,Wouter W. de Herder,Renato Cozzi,Mirtha Guitelman,Flavia Magri,Maria Stefania Lagonigro,Georges Halaby,Vinciane Corman,Marie-Thérèse Hagelstein,Jean-Francis Vanbellinghen,Gustavo Barcelos Barra,Anne-Paule Gimenez-Roqueplo,Fergus J. Cameron,Françoise Borson-Chazot,Ian M. Holdaway,Sergio P. A. Toledo,Günter K. Stalla,Anna Spada,Sabina Zacharieva,Jérôme Bertherat,Thierry Brue,Vincent Bours,Philippe Chanson,Lauri A. Aaltonen,Albert Beckers +63 more
TL;DR: Prisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility.
Journal ArticleDOI
Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families
Adrian Daly,Jean-François Vanbellinghen,Sok Kean Khoo,Marie Lise Jaffrain-Rea,Luciana Ansaneli Naves,Mirtha Guitelman,Arnaud Murat,Philippe Emy,Anne-Paule Gimenez-Roqueplo,Guido Tamburrano,Gérald Raverot,Anne Barlier,Wouter W. de Herder,Alfred Penfornis,Enrica Ciccarelli,Bruno Estour,P. Lecomte,Blandine Gatta,Olivier Chabre,Maria Isabel Sabaté,Xavier Bertagna,Natalia Garcia Basavilbaso,Graciela Stalldecker,Annamaria Colao,Piero Ferolla,Jean-Louis Wémeau,Philippe Caron,Jean-Louis Sadoul,Adriana Oneto,F. Archambeaud,Alain Calender,Olga Sinilnikova,Carmen Fajardo Montañana,Francesco Cavagnini,Vaclav Hana,Angela R. Solano,Dreanina Delettieres,Douglas C. Luccio-Camelo,Douglas C. Luccio-Camelo,Armando Basso,Vincent Rohmer,Thierry Brue,Vincent Bours,Bin Tean Teh,Albert Beckers +44 more
TL;DR: AIP mutations, of which nine new mutations have been described here, occur in approximately 15% of FIPA families, and although pituitary tumors occurring in association with AIP mutations are predominantly somatotropinomas, other tumor types are also seen.
Journal ArticleDOI
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Mônica R. Gadelha,Marcello D. Bronstein,Thierry Brue,Mihail Coculescu,Maria Fleseriu,Mirtha Guitelman,Vyacheslav Pronin,Gérald Raverot,Ilan Shimon,Kayo Kodama Lievre,Juergen Fleck,Mounir Aout,Alberto M Pedroncelli,Annamaria Colao +13 more
TL;DR: Pasireotide provides superior efficacy compared with continued treatment with octreotide or lanreotide, and could become the new standard pituitary-directed treatment in patients with acromegaly who are inadequately controlled using first-generation somatostatin analogues.
Journal ArticleDOI
Retrospective multicentric study of pituitary incidentalomas.
Patricia Fainstein Day,Mirtha Guitelman,Rosa Artese,León Fiszledjer,A. Chervin,Nicolas Marcelo Vitale,Graciela Stalldecker,Valeria de Miguel,Dora Cornaló,Analía Alfieri,María Susana,Mallea Gil +11 more
TL;DR: A high percentage of PIs are macro-incidentalomas against expectations from necropsy and imaging studies, and most macro-PIs are found in males and are clinically non-functioning adenomas, 37% requiring surgery and hormonal substitution.
Journal ArticleDOI
Primary empty sella (PES): a review of 175 cases.
Mirtha Guitelman,Natalia Garcia Basavilbaso,Marcelo Vitale,A. Chervin,David F. Katz,Karina Miragaya,J. Herrera,D. Cornaló,Marisa Servidio,Laura Boero,Marcos Manavela,Karina Danilowicz,Analía Alfieri,Graciela Stalldecker,Mariela Glerean,P. Fainstein Day,Carolina Ballarino,Maria Susana Mallea Gil,Amelia Rogozinski +18 more
TL;DR: In most patients, PES was discovered as an incidental finding on imaging studies, while in almost a quarter of patients PESwas found during the diagnostic evaluation of anterior pituitary deficiency, which was more common in men.